Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
IDH2 mutation + Chr del(1p) + Chr del(19q) + NTRK2 fusion
Cancer:
Oligodendroglioma
Drug:
Vitrakvi (larotrectinib)
(
TrkB receptor inhibitor
,
TrkC kinase inhibitor
,
TrkA receptor inhibitor
)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
NCCN
Excerpt:
ADULT GLIOMA: OLIGODENDROGLIOMA (IDH-MUTANT, 1p19q CODELETED)….Recurrent or Progressive Disease WHO grade 2, KPS ≥60...Useful in Certain Circumstances...NTRK gene fusion tumors...Larotrectinib
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login